15 Sep. 2023 J. Molner AS Consolidated Unaudited Interim Report for the First 6 Months of 2023 and increase of The J. Molner Company OÜ voluntary reserve
6 Sep. 2023 J. Molner Signs Licensing Agreement for Five Approved Drugs in the US
2 Aug. 2023 Restructuring in the employee structure of J.Molner AS subsidiary The J. Molner Company OÜ
13 Jul. 2023 J. Molner submits drug application to U.S Food and Drug Administration (FDA)
8 Jun. 2023 J. Molner AS Announces Historic Milestone: Receives Health Canada Approval for its First Drug, Norepinephrine Bitartrate Injection
28 Apr. 2023 Restructuring in the employee structure of J.Molner AS subsidiary The J. Molner Company OÜ
20 Apr. 2023 J.Molner AS Resolutions of annual general meeting
10 Apr. 2023 J.Molner concludes loan agreement extending the existing credit facility of The J. Molner Company OÜ
6 Apr. 2023 J. Molner announces licensing agreement for generic injectable drugs with Juno Pharmaceuticals in Canada
28 Mar. 202 Notice of calling the annual general meeting of the shareholders
28 Mar. 2023 J.Molner submits second drug to Health Canada
17 Mar. 2023 J.Molner AS comments on the observation status applied on J.Molner AS shares on March 10, 2023 by Nasdaq Tallinn
10 Mar. 2023 J.Molner AS Audited Annual Reports 2022
10 Mar. 2023 J.Molner AS Unaudited Interim Reports 2022
9 Jan. 2023 J. Molner AS executes planned reorganization transaction
30 Nov. 2022 The first day of trading with new shares of J.Molner AS is 01.12.2022
14 Nov. 2022 FDA formally registers transfer to J. Molner AS of 3 drugs
7 Nov. 2022 Results of the initial public offering of J. Molner AS shares
27 Oct. 2022 J. Molner AS comment about the tenure of Jason Grenfell-Gardner at Teligent, Inc
24 Oct. 2022 Notice of initial public offering of J. Molner AS shares
19 Oct. 2022 Conditional admission to trading of J.Molner AS shares on Nasdaq Baltic Alternative market First North
